Note 10 – Inventories

million CHF

 

2018

 

2017

 

 

 

 

 

Inventories

 

1,359

 

1,288

Value adjustments

 

(109)

 

(111)

Total

 

1,250

 

1,177

million CHF

 

2018

 

2017

 

 

 

 

 

 

 

 

 

Raw materials

 

25%

 

315

 

25%

 

292

Work in progress

 

9%

 

115

 

6%

 

67

Finished goods

 

51%

 

639

 

50%

 

594

Other

 

14%

 

181

 

19%

 

224

Total

 

100%

 

1,250

 

100%

 

1,177

By operating segments:

million CHF

 

2018

 

12017

1

Restated following the 2018 integration of the Capsugel segment into Lonza Pharma & Biotech and Lonza Specialty Ingredients.

 

 

 

 

 

 

 

 

 

Pharma & Biotech

 

65%

 

816

 

54%

 

639

Specialty Ingredients

 

35%

 

434

 

46%

 

538

Total

 

100%

 

1,250

 

100%

 

1,177

Inventory Write-Downs

million CHF

 

Raw materials

 

Work in progress and finished goods

 

Other

 

Total 2018

 

Total 2017

 

 

 

 

 

 

 

 

 

 

 

At 1 January

 

14

 

57

 

40

 

111

 

109

Increase

 

7

 

194

 

4

 

205

 

295

Reversal / Utilization of write-downs

 

(5)

 

(193)

 

(3)

 

(201)

 

(292)

Reclassification to assets held for sale

 

0

 

(2)

 

(2)

 

(4)

 

0

Currency translation differences

 

0

 

(2)

 

0

 

(2)

 

(1)

At 31 December

 

16

 

54

 

39

 

109

 

111

The cost of inventories recognized as expenses during the period and included in «Cost of goods sold» amounted to CHF 3,599 million (2017: CHF 3,072 million).